Alcimed - BigPharma Case - Printout 1 - 2021

Alcimed – BigPharma Case
2021
1 April 2020 I
Case Study: BigPharma
Product Portfolio Pipeline Review

Help BigPharma to stratify and concentrate on the most promising areas of activity!
Background
BigPharma has a long history in diabetes and oncology. Currently, BigPharma has 2 drugs in diabetes
and 3 products in oncology for multiple myeloma, besides some activities in other fields as well. As a
large pharmaceutical company performing research and development, BigPharma is driving a
blockbuster business model. That means having high upfront R&D expenditures with relatively high
number of development failures in order to develop few new drugs with a very high revenue.
After R&D, the cost for production are comparably low. Sales, however, is a key success factor for big
pharmaceutical companies as well.
Their global sales force is split in the ratio 3 (Diabetes) to 1 (Oncology).
BigPharma is only active in Europe. BigPharma does not expect to increase the sales force for the
launch of new products, but thinks it is possible to drive sales as estimated with the available force.
“We need to concentrate on the best candidates” says the Head of R&D. “We cannot go full scope on all
promising candidates at the same time”
In 2019, BigPharma is looking for a strategic review of their current product pipeline, to stratify and
concentrate on the most promising areas of activity. Currently, they have 4 candidates in phase II and
phase III clinical trials and want to push the most promising 2 candidates as much as possible.
2 April 2020 I
Pharma development funnel

Drug development in clinical trials is a very selective process
Drug Candidates
Drug Candidates
Phase I Phase II Phase III New Drug
Drug Candidates
Drug Candidates
Probability of Phase I Phase II Phase III TOTAL

success*
Diabetes 10 % 50 % 80 % 4%
Oncology 8% 25 % 60 % 1,2 %
3 April 2020 I
*Values derived from BigPharma experience in past developments
Medical Need Multiple Myeloma / Oncology

Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment
of cancer. Multiple myeloma is a cancer of plasma cells.
▪ BigPharma specialized in Multiple Myeloma.

▪ Multiple myeloma (MM), also known as plasma cell myeloma,
is a cancer of plasma cells, a type of white blood cell which Diagnosed Incident Cases of MM,
normally produces antibodies.
Both Sexes, Ages ≥40 Years, 2017 and 2027
▪ With high-dose therapy followed by ASCT (autologous
hematopoietic stem-cell transplantation), the median survival has
been estimated in 2003 to be about 4,5 years, compared to a
median around 3,5 years with "standard" therapy. Overall the 5-
year survival rate is around 35%.
▪ Treatment may not be needed if no symptoms are being

experienced (smoldering MM). However, periodic blood and urine
tests help physicians monitor for signs of disease progression.
▪ If symptoms occur or MM shows signs of progression, treatment

can help to relieve pain, control the complications of the disease,
stabilize the condition, and slow down the progress of the disease.
Although there is no cure for MM, with good treatment results it is
usually possible for patients to return to near-normal lifestyle.
▪ Diagnosed Incident Cases reflect the cases, in which treatment is

necessary.
4
Source: Multiple Myeloma: Epidemiology Forecast to 2027, Globaldata.com April 2020 I
Medical Need Diabetes
In 2017, 425 million people worldwide had diabetes, up from an estimated
382 million people in 2013 and from 108 million in 1980.
▪ Diabetes mellitus (DM) which is commonly known as diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a
prolonged period.
▪ Type 1 diabetes results from the pancreas's failure to produce enough insulin due to loss of beta cells. The loss of beta cells is caused by an
autoimmune response. The cause of this autoimmune response is unknown.
▪ Type 2 diabetes begins with insulin resistance, a condition in which cells fail to respond to insulin properly. As the disease progresses, a lack of insulin
may also develop. The most common cause is a combination of excessive body weight and insufficient exercise.
▪ In 2017, 425 million people worldwide had diabetes

▪ Type 2 makes up about 90% of the cases.
Population Diabetes
2019 Values (million | people) prevalence
EU Big 5 321.9 321 902 732 8.1 %
US 327.2 327 204 005 7.4%
China 1 386.0 1 386 034 583 8.5%
5 April 2020 I
❖ Key question: “Which drug candidate has the most
potential for BigPharma?”
❖ During the session, we will:

▪ Introduce Alcimed
▪ Go through the briefing material
▪ Discuss possible approaches using live quiz
▪ Answer the key question using the briefing and the associated asset cards

Alcimed - BigPharma Case - Printout 1 - 2021

Uploaded by

Copyright:

Available Formats

Alcimed - BigPharma Case - Printout 1 - 2021

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Alcimed - BigPharma Case - Printout 1 - 2021

Uploaded by

Copyright:

Available Formats

Alcimed – BigPharma Case

Product Portfolio Pipeline Review

Pharma development funnel

Probability of Phase I Phase II Phase III TOTAL

Medical Need Multiple Myeloma / Oncology

▪ BigPharma specialized in Multiple Myeloma.

▪ Treatment may not be needed if no symptoms are being

▪ If symptoms occur or MM shows signs of progression, treatment

▪ Diagnosed Incident Cases reflect the cases, in which treatment is

▪ In 2017, 425 million people worldwide had diabetes

❖ During the session, we will:

You might also like